Isofol Medical AB (publ) (ISOFOL.ST)
SEK 1.93
(3.66%)
SEK 1.93
(3.66%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 140.59 Million SEK | -34.14% |
| 2022 | 213.46 Million SEK | -46.82% |
| 2021 | 401.36 Million SEK | 170.95% |
| 2020 | 148.13 Million SEK | 1.13% |
| 2019 | 146.47 Million SEK | -49.24% |
| 2018 | 288.55 Million SEK | -20.13% |
| 2017 | 361.27 Million SEK | 1478.31% |
| 2016 | 22.89 Million SEK | 134.12% |
| 2015 | 9.77 Million SEK | 0.0% |
| 2011 | 10.37 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 132.03 Million SEK | -6.09% |
| 2024 Q2 | 123.86 Million SEK | -6.19% |
| 2023 Q1 | 172.09 Million SEK | -19.38% |
| 2023 Q2 | 161.83 Million SEK | -5.96% |
| 2023 Q3 | 150.13 Million SEK | -7.23% |
| 2023 Q4 | 140.59 Million SEK | -6.35% |
| 2023 FY | 140.59 Million SEK | -34.14% |
| 2022 Q2 | 298.56 Million SEK | -14.83% |
| 2022 Q1 | 350.56 Million SEK | -12.66% |
| 2022 FY | 213.46 Million SEK | -46.82% |
| 2022 Q4 | 213.46 Million SEK | -16.63% |
| 2022 Q3 | 256.05 Million SEK | -14.24% |
| 2021 Q3 | 453.92 Million SEK | -18.91% |
| 2021 Q1 | 105.43 Million SEK | -28.83% |
| 2021 Q2 | 559.78 Million SEK | 430.95% |
| 2021 FY | 401.36 Million SEK | 170.95% |
| 2021 Q4 | 401.36 Million SEK | -11.58% |
| 2020 FY | 148.13 Million SEK | 1.13% |
| 2020 Q4 | 148.13 Million SEK | -21.04% |
| 2020 Q2 | 209.86 Million SEK | 120.81% |
| 2020 Q1 | 95.04 Million SEK | -35.11% |
| 2020 Q3 | 187.6 Million SEK | -10.61% |
| 2019 Q3 | 207.74 Million SEK | -13.16% |
| 2019 Q2 | 239.21 Million SEK | -10.87% |
| 2019 FY | 146.47 Million SEK | -49.24% |
| 2019 Q4 | 146.47 Million SEK | -29.5% |
| 2019 Q1 | 268.38 Million SEK | -6.99% |
| 2018 Q1 | 345.05 Million SEK | -4.49% |
| 2018 Q2 | 321.69 Million SEK | -6.77% |
| 2018 Q4 | 288.55 Million SEK | -5.4% |
| 2018 FY | 288.55 Million SEK | -20.13% |
| 2018 Q3 | 305.03 Million SEK | -5.18% |
| 2017 Q1 | 9.02 Million SEK | -60.59% |
| 2017 FY | 361.27 Million SEK | 1478.31% |
| 2017 Q4 | 361.27 Million SEK | -4.28% |
| 2017 Q3 | 377.44 Million SEK | -5.34% |
| 2017 Q2 | 398.74 Million SEK | 4320.14% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q4 | 22.89 Million SEK | 0.0% |
| 2016 FY | 22.89 Million SEK | 134.12% |
| 2015 Q4 | 9.77 Million SEK | 0.0% |
| 2015 FY | 9.77 Million SEK | 0.0% |
| 2011 FY | 10.37 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 6.07 Million SEK | -2213.592% |
| BioArctic AB (publ) | 1.18 Billion SEK | 88.146% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -601.547% |
| CombiGene AB (publ) | 120.61 Million SEK | -16.57% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 35.22% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -365.969% |
| OncoZenge AB (publ) | 20.34 Million SEK | -591.234% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -18.697% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 92.602% |
| Mendus AB (publ) | 755.95 Million SEK | 81.401% |
| LIDDS AB (publ) | 17.65 Million SEK | -696.358% |
| Lipum AB (publ) | 12.11 Million SEK | -1060.999% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 49.561% |
| Simris Alg AB (publ) | 174.55 Million SEK | 19.453% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -165.352% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -547.827% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 78.486% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 81.628% |
| Ziccum AB (publ) | 14.97 Million SEK | -839.066% |
| AcouSort AB (publ) | 34.51 Million SEK | -307.374% |
| Active Biotech AB (publ) | 44 Million SEK | -219.539% |
| Alzinova AB (publ) | 123.18 Million SEK | -14.131% |
| Amniotics AB (publ) | 26.08 Million SEK | -438.975% |
| Camurus AB (publ) | 1.9 Billion SEK | 92.63% |
| Cantargia AB (publ) | 223.71 Million SEK | 37.153% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -845.571% |
| Genovis AB (publ.) | 288.85 Million SEK | 51.326% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -64.968% |
| Intervacc AB (publ) | 259.61 Million SEK | 45.843% |
| Kancera AB (publ) | 65.64 Million SEK | -114.184% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 88.827% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -318.419% |
| NextCell Pharma AB | 81.28 Million SEK | -72.962% |
| Saniona AB (publ) | 64.14 Million SEK | -119.193% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 71.668% |
| Xintela AB (publ) | 18.39 Million SEK | -664.322% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -125.399% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -235.082% |
| Corline Biomedical AB | 100.1 Million SEK | -40.45% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 20.621% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -126.215% |
| Aptahem AB (publ) | 63.02 Million SEK | -123.082% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 59.982% |
| Fluicell AB (publ) | 9.34 Million SEK | -1405.321% |
| Biovica International AB (publ) | 131.4 Million SEK | -6.993% |
| Abliva AB (publ) | 87.49 Million SEK | -60.684% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 81.505% |
| 2cureX AB (publ) | 16.62 Million SEK | -745.696% |
| I-Tech AB | 152.44 Million SEK | 7.771% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 86.189% |
| Cyxone AB (publ) | 43.65 Million SEK | -222.064% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -78.667% |
| Biosergen AB | 7.2 Million SEK | -1852.465% |
| Nanologica AB (publ) | 77.42 Million SEK | -81.582% |
| SynAct Pharma AB | 228.01 Million SEK | 38.34% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -425.341% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 89.959% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 41.019% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -1562.886% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -61.472% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -393.184% |